| |
| Issue |
Title |
| |
| No 4 (2024) |
Implementation of quantitative integral analysis in assessing events associated with safety issues during clinical trials: focusing on trastuzumab |
Abstract
PDF (Rus)
|
|
A. B. Verveda, V. B. Vasilyuk, G. I. Syraeva, M. V. Faraponova, A. V. Popov |
| |
| No 4 (2024) |
Potential use of nanoparticles to improve the effectiveness and safety of pharmacotherapy during pregnancy |
Abstract
PDF (Rus)
|
|
K. A. Zagorodnikova, O. A. Bettikher, I. Ye. Zazerskaya |
| |
| No 2 (2024) |
Monitoring and safety assessment of drug-drug interactions in elderly patients |
Abstract
PDF (Rus)
|
|
A. T. Sharaeva, A. A. Zurdinova, A. T. Satybaldieva |
| |
| No 2 (2024) |
Ineffectiveness of carbapenems in real-world clinical practice according to therapeutic drug monitoring data and Roszdravnadzor AIS reports |
Abstract
PDF (Rus)
|
|
O. V. Zhukova, N. N. Chesnokova, O. A. Vorobeva, I. E. Pogodin, I. Yu. Shirokova |
| |
| No 1 (2024) |
Adverse drug events among hospitalized COVID-19 patients. Experience with the Global Trigger Tool |
Abstract
PDF (Rus)
|
|
S. A. Mishinova, A. S. Kolbin, E. V. Verbitskaya, N. P. Alekseeva, Yu. M. Gomon |
| |
| No 1 (2024) |
Relationship between renal damage marker levels and the presence of bleeding in patients with atrial fibrillation and chronic kidney disease receiving rivaroxaban |
Abstract
PDF (Rus)
|
|
N. A. Shatalova, O. D. Ostroumova, T. N. Korotkova, I. V. Vorozhko, E. V. Klychnikova, E. Yu. Ebzeeva, M. A. Godkov, A. V. Starodubova, K. B. Mirzaev, D. A. Sychev |
| |
| No 2 (2023) |
Neurotoxicity in the treatment of Parkinson's disease |
Abstract
PDF (Rus)
|
|
N. Ya. Siritsa |
| |
| No 3 (2022) |
The use of a new oral antiviral drug molnupiravir in the treatment of COVID-19 from a safety perspective |
Abstract
PDF (Rus)
|
|
A. L. Khokhlov, J. V. Rybachkova |
| |
| No 3 (2022) |
Polypharmacy problems in geriatric practice of Kyrgyz Republic |
Abstract
PDF (Rus)
|
|
A. T. Sharaeva, A. A. Zurdinova |
| |
| No 2 (2022) |
Drug-induced intracerebral hemorrhage |
Abstract
PDF (Rus)
|
|
A. I. Listratov, T. M. Ostroumova, A. I. Kochetkov, O. D. Ostroumova |
| |
| No 1 (2022) |
Drug-induced pulmonary artery hypertension |
Abstract
PDF (Rus)
|
|
O. D. Ostroumova, A. I. Listratov, A. I. Kochetkov, S. A. Bliznyuk, A. G. Komarova, D. A. Sychev |
| |
| No 3 (2021) |
Food-drug interaction as a risk factor of drug-induced diseases: epidemiology, risk factors, potential mechanisms of interaction |
Abstract
PDF (Rus)
|
|
A. P. Pereverzev, O. D. Ostroumova |
| |
| No 3 (2021) |
Associations of CYP2D6, ABCB1 2677G>T/A and 3435C>T with effectiveness and safety of pharmacotherapy for acute psychotic episodes in adolescents over 28 days |
Abstract
PDF (Rus)
|
|
D. V. Ivaschenko, N. I. Buromskaya, P. V. Shimanov, R. V. Deitsch, M. I. Nastovich, K. A. Akmalova, A. A. Kachanova, E. A. Grishina, L. M. Savchenko, Y. S. Shevchenko, D. A. Sychev |
| |
| No 2 (2021) |
Drugs associated with drug-induced interstitial lung diseases |
Abstract
PDF (Rus)
|
|
O. D. Ostroumova, A. I. Listratov, A. I. Kochetkov, D. A. Sychev |
| |
| No 2 (2021) |
Alcohol as a risk factor for drug-induced diseases |
Abstract
PDF (Rus)
|
|
D. A. Sychev, O. D. Ostroumova, A. P. Pereverzev, A. I. Kochetkov, T. M. Ostroumova, E. Yu. Ebzeeva, M. V. Klepikova |
| |
| No 3 (2020) |
Drug-induced liver damage with cholestasis |
Abstract
PDF (Rus)
|
|
A. P. Pereverzev, O. D. Ostroumova, A. I. Kochetkov |
| |
| No 4 (2019) |
Cardiovascular complications of immune checkpoint inhibitors |
Abstract
PDF (Rus)
|
|
A. A. Kulievа, E. I. Emelina, G. E. Gendlin, I. G. Nikitin, S. K. Zyryanov, S. I. Varentsov, I. I. Zakharova |
| |
| No 2 (2019) |
Systemic characteristic of safety profile of monoclonal antibodies used in rheumatology practice |
Abstract
PDF (Rus)
|
|
A. V. Philippova, A. S. Kolbin, E. V. Verbitskaya, S. V. Glagolev, V. A. Polivanov |
| |
| No 2 (2019) |
Pharmacology in special populations: extreme age |
Abstract
PDF (Rus)
|
|
B. K. Romanov, S. K. Zyryanov |
| |
| No 3 (2018) |
Modern aspects of epidemiology of congenital anomalies of development: methodological issues and the translation of research fndings into clinical practice |
Abstract
PDF (Rus)
|
|
O. V. Reshetko, K. V. Lutsevich |
| |
| No 1 (2004) |
Основные механизмы развития неблагоприятных побочных реакций |
Abstract
PDF (Rus)
|
|
, |
| |
| No 2 (2005) |
Клиническая фармакогенетика: тернистый путь внедрения в клиническую практику |
Abstract
PDF (Rus)
|
|
|
| |
| No 2 (2005) |
Возможности применения лизиноприла при заболеваниях печени |
Abstract
PDF (Rus)
|
|
, |
| |
| No 3 (2008) |
Полипрагмазия и лекарственные взаимодействия у пожилых пациентов |
Abstract
PDF (Rus)
|
|
, |
| |
| 1 - 24 of 44 Items |
1 2 > >>
|
